Assignee
DENALI THERAPEUTICS INC
US·52 granted patents·70 pending applications·169 citations·filing 2016–2025
Top patents by PatentIndex Score
122 records- 0197US11111235B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·7 cites·26 claims
- 0297US9896458B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Feb 20, 2018·23 cites·6 claims
- 0397US9815850B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·36 cites·41 claims
- 0496US11912778B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·2 cites·17 claims
- 0596US10143187B2Transferrin receptor transgenic modelsDENALI THERAPEUTICS INC·Filed 2018·Granted Dec 4, 2018·12 cites·34 claims
- 0696US9932325B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Apr 3, 2018·16 cites·30 claims
- 0795US11124567B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Sep 21, 2021·16 cites·31 claims
- 0895US10457717B2Engineered polypeptidesDENALI THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·11 cites·29 claims
- 0993US12162948B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Granted Dec 10, 2024·1 cites·16 claims
- 1093US10870837B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·9 cites·47 claims
- 1191US11884944B2Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·39 claims
- 1291US11306077B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Apr 19, 2022·2 cites·47 claims
- 1391US10370361B2Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of productionDENALI THERAPEUTICS INC·Filed 2018·Granted Aug 6, 2019·3 cites·27 claims
- 1490US11591316B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·1 cites·20 claims
- 1590US10590114B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 17, 2020·5 cites·27 claims
- 1689US11866742B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2020·Granted Jan 9, 2024·2 cites·35 claims
- 1789US11643446B2Progranulin variantsDENALI THERAPEUTICS INC·Filed 2022·Granted May 9, 2023·4 cites·50 claims
- 1889US2025034119A1Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1988US11795232B2Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2019·Granted Oct 24, 2023·2 cites·38 claims
- 2088US2024141058A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2187US2024018253A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2286US10604535B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·3 cites·18 claims
- 2386US10131676B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·3 cites·33 claims
- 2485US12358928B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·8 claims
- 2585US11834439B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2023·Granted Dec 5, 2023·0 cites·19 claims
- 2685US2025297023A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2784US2025388601A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2883US11203600B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 21, 2021·2 cites·24 claims
- 2982US2024024432A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3082US2024271326A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3180US11236100B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·1 cites·30 claims
- 3280US2025011338A1Kinase Inhibitors and Uses ThereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3379US12240902B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Mar 4, 2025·1 cites·20 claims
- 3479US11834438B2Process for the preparation of pyrimidinyl-4-aminopyrazole compoundsDENALI THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·1 cites·6 claims
- 3579US2026079170A1Methods for treating and monitoring progranulin-associated disordersDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3679US2024140919A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3778US10851088B2Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of productionDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 1, 2020·1 cites·25 claims
- 3878US2025367284A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3978US2025387477A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4076US11028080B2Substituted pyrimidines as LRKK2 inhibitorsDENALI THERAPEUTICS INC·Filed 2017·Granted Jun 8, 2021·1 cites·53 claims
- 4176US2023381286A1Affinity-based methods for using transferrin receptor-binding proteinsDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4276US2023250072A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4375US11851440B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·18 claims
- 4475US2025122159A1Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4574US12497387B2Process for the preparation of pyrimidinyl-4-aminopyrazole compoundsDENALI THERAPEUTICS INC·Filed 2023·Granted Dec 16, 2025·0 cites·5 claims
- 4674US11427571B2Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of productionDENALI THERAPEUTICS INC·Filed 2020·Granted Aug 30, 2022·0 cites·2 claims
- 4774US2023265137A1Progranulin variantsDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4873US12139478B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2024·1 cites·57 claims
- 4973US2024150736A1Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5073US2023043400A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 122 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DENALI THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →